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Nephrotic syndrome (NS) is 15 times more common in children than in adults. NS affects 1-3/100,000 children <16 years of age [1,2]. As defined by the International 
Study of Kidney Disease in Children (ISKDC), NS is characterized 
by proteinuria (>40 mg/m2/h), hypoalbuminemia (<2.5 g/dL), 
edema, and usually hypercholesterolemia >200 mg/dL [1-3]. 
Two-thirds of childhood NS present before the age of 6 years. 
The ratio of boys to girls is 2:1. By late adolescence, both sexes 
are equally affected. 90% of childhood cases are not associated 
with any systemic disease and is classified as primary NS [3]. 
Without treatment, NS in children is associated with a high risk 
of death, most commonly from infections [2]. Fortunately, 80% 
of the children with idiopathic NS show remission of proteinuria 
following treatment with corticosteroids and are classified as 
‘steroid sensitive’ (SS), and they usually have minimal change 
disease on histopathology [3]. However, in some regions, there 
have been differences to these findings based on the race [4].
Although glucocorticoid therapy is standard therapy for NS, 
neither the target cell nor the mechanism of action of steroids 
has been determined [2]. The majority of children with NS 
relapse within the first 6 months of initial therapy. Relapses 
are often triggered by the upper respiratory or gastrointestinal 
infections [2]. Frequent relapses (FRs) are at high risk of 
developing complications related to steroid therapy as they 
need repeated courses of steroid for treatment and they are more 
prone for systemic infections also. There were studies predicting 
some factors for relapse in NS [5,6]. If such relapses could be 
predicted at the onset of disease, it would lead to better long-term 
management of the disease. Therefore, we planned this study with 
an objective to identify the risk factors for FR in childhood steroid 
sensitive NS (SSNS).
METHODS
This prospective study was conducted at Pediatric Nephrology 
Clinic in the Government Dharmapuri Medical College Hospital, 
Tamil Nadu, between July 2013 and January 2016. Cases with 
the first episode of idiopathic SSNS in the age group of 9 months 
- 12 years, who followed up for at least 12 months were enrolled 
in the study. Children with incomplete data at initial presentation, 
congenital and secondary forms of NS, <12 months follow-up, or 
previous treatment with steroids or immunosuppressive agents, 
and steroid resistant NS were excluded from the study. NS was 
diagnosed in accordance with standard criteria [3].
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The laboratory evaluation of the child with the first 
episode of NS included urinalysis, first-morning urine protein: 
Creatinine ratio (PCR), complete blood count, blood urea, serum 
creatinine, electrolytes, and albumin, and serum cholesterol 
levels. Serum C3 and anti-streptolysin O was done in the 
presence of microscopic hematuria. Chest X-ray and Mantoux 
testing was done to rule out pulmonary infiltrates and ultrasound 
abdomen to rule out renal anomalies. Urine for protein/albumin 
was done routinely to assess the treatment response as well as 
for follow-up.
The children were treated as per revised guidelines for the 
management of SSNS by Indian Pediatric Nephrology Group [7]. 
Children with the first episode of NS are treated with oral 
prednisolone 2 mg/kg daily for 6 weeks (60 mg/m2/day) followed 
by 1.5 mg/kg on alternate days for 6 weeks (40 mg/m2/every 
another day). At the end of 12 weeks, steroids were stopped, and 
children are monitored weekly for signs of relapse. Following 
steroid therapy, children with NS undergo anyone of the following 
responses.
Remission
It was indicated by the absence of albumin by Albustix on 
three consecutive early morning urine samples (or proteinuria 
<4 mg/m2/h).
Relapse
Urine albumin 3+ or 4+ (or proteinuria >40 mg/m2/h) for three 
consecutive early morning specimens, having been in remission 
previously.
Frequent Relapser (FR)
Two or more relapses in initial 6 months or more than three 
relapses in any 12 months.
Infrequent Relapser (IFR)
About <2 relapses within 6 months of the initial response or <4 
relapses for any year thereafter.
Steroid Dependence
Two consecutive relapses during alternate day steroid therapy or 
within 14 days of stopping steroids.
Steroid Resistant NS
Inability to induce a remission within 4 weeks of a daily dose of 
2 mg/kg/day of prednisolone therapy.
Children with SSNS were divided into 2 groups: (1) FR and 
(2) IFR. The following factors were studied as possible risk factors 
for relapse between 2 groups: Age at onset, sex, serum albumin, 
24 h urine protein, azotemia, time taken to achieve remission 
during the first episode, duration of interval between remissions 
and first relapse, associated infections and hypertension.
The data collected were coded, edited and entered into 
computer and were analyzed using a statistical software package, 
SPSS version 10.00. Student’s t-test was used to compare the 
mean values, and Chi-squared test (χ2) was used to compare the 
frequencies. For testing the statistical significance of difference 
between the different parameters, a p<0.05 was considered as 
significant. Informed consent by parents and Institutional Ethical 
Committee clearance was obtained.
RESULTS
A total of 178 children with NS were screened for the possible 
inclusion during the study period. 18 were excluded because 12 of 
them had no relapse during the 1 year follow-up and 6 were lost 
to follow-up (4 steroid resistant). There were 97 male children 
(60.6%), 63 female children (39.4%) with a male to female ratio 
of 1.5:1. The mean age of presentation was 4.37±2.32 years. There 
were 92 children with IFR and 68 children with FR (Figure 1). 
The mean time taken to achieve remission during the first episode 
is 1.94±1.04 weeks. The duration of interval between remission 
and first relapse was 5.56±4.51 months. Incidence of infection 
and hypertension was 31.9% and 37.5%, respectively (Table 1).
Incidence of FR was high in 1-8 years age group. There were 
81 IFR (57.45%) and 60 FR (42.55%); however, the correlation 
was not statistically significant (p=0.4059) (Table 2). The 
incidence of FR was less in males than in females; but it was 
not significant (p=0.0609) (Table 2). Majority of the children 
with IFR responded to steroid therapy in <2 weeks, while the 
most children with FR showed response after 3-4 weeks. The 
time taken to achieve remission during the first episode was 
2.9±0.81 weeks for the FR children and for the IFR children; it 
was 1.24±0.48 weeks (p=0.0001) (Table 3). Hence, the children 
who took more than 14 days to achieve remission during the first 
episode were affected with FR.
Majority of the children (90%) in IFR relapsed after 
6 months, while in FR group children (76%) relapsed before 
6 months. Statistically significant (p=0.0001) difference was 
Figure 1: Flow diagram of cases in study
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seen between the duration of interval between remission and first 
relapse for the children with FR (4.74±2.6 months) and with IFR 
(9.39±2.09 months) (Table 3). In 6.5% children with IFR, history 
of infections (urinary tract and respiratory tract) was present in 
comparison to 66.2% children with FR (p=0.0001) (Table 3). 
Incidence of hypertension was significantly higher (p=0.0001) in 
children with FR (80.9%) than in children with IFR (5.4%) as 
shown in Table 3.
However, serum albumin, 24 h urine protein, and azotemia 
values were not associated with increased risk of the FR in 
our study. The serum albumin values of the children with FR 
(2.27±0.34) did not differ significantly from that of the IFR 
children (2.32±0.34 mg/dl) (p=0.3743). Similarly, 24 h urine 
proteins of FR (1188.5±562.2) and IFR (1234.3±607) children 
showed no significant difference (p=0.7647). Majority of the 
children in both the groups had normal renal function tests.
DISCUSSION
NS generally tends to follow a benign and chronic relapsing 
course, but a few patients may have serious or fatal complications. 
Previous studies have shown that around 80-90% of the patients 
with childhood NS relapse which is consistent with the findings in 
our study [8,9]. FR children needed prolonged course of steroids, 
increasing the risk of steroid toxicity. Increased incidence of 
steroid toxicity also occurs when children require frequent course 
of prednisolone therapy. This includes, inter alia, cushingoid 
appearance, behavioral changes, hypertension, obesity, glucose 
intolerance, cataract, osteopenia, and decreased growth rate [3]. 
All these complications impact the daily life children with NS.
The relapse pattern is thought to be dependent on numerous 
factors identified by various investigators and includes age 
at onset, sex and time to remission after first relapse, degree 
of albuminuria, hypertension, hematuria, infections, and time 
taken to achieve remission [5-6,9-18]. In our study, age at 
onset, sex, serum albumin, 24 h urine protein, and azotemia did 
not influence the frequency of subsequent relapses. More than 
14 days to achieve remission during the first episode, relapse 
within first 6 months, associated infections and hypertension 
were significantly associated with FRs in our study.
This study showed a predominance of male patients over 
females, and the result was similar to studies elsewhere [9-11]. 
The most common age group at presentation was 1-8 years, 
which was also noticed in the previous studies from different 
regions [10,12-14]. In our study, IFR (57.5%) in children was 
more common compared to FR (42.5%). Similar findings were 
reported by Prasun et al. [9] and Noer et al. [18]. However, in 
several studies, FR was more common than the IFR [5,10,11]. 
Table 1: Relapse pattern and risk factors in steroid sensitive 
nephrotic syndrome children (n=160)





Male female ratio 1.5:1
Serum albumin (mg/dl) 2.3±0.344
24 h urine protein 1214.8±587
Azotemia 24.07±6.44
Time taken to achieve 
remission (weeks)
1.94±1.04
Interval between remission and first 
relapse (months)
5.56±4.51
Mean number of relapses 1.33
Incidence of infection 31.9
Incidence of hypertension 37.5
FR: Frequent relapse, IFR: Infrequent relapse, SD: Standard deviation
Table 3: Factors significantly correlated with FR (n=160)




Time taken to achieve remission 
during first episode (weeks)
1 72 (78.3) 7 (10.3) 0.0001
2 18 (19.6) 5 (7.4)
3 2 (2.2) 44 (64.7)
4 - 12 (17.6)
Mean±SD 1.24±0.48 2.9±0.81
Duration of interval 
between remission and first 
relapse (months)
0-1 5 (5.4) 4 (5.8) 0.0001
1-6 4 (4.3) 48 (70.5)
>6 83 (90.2) 16 (23.5)
Mean±SD 9.39±2.09 4.74±2.6
Infections (urinary tract and 
respiratory infections)
Present 6 (6.5) 45 (66.2) 0.0001
Absent 86 (93.5) 23 (33.8)
Hypertension
Present 5 (5.4) 55 (80.9) 0.0001
Absent 87 (94.6) 13 (19.1)
FR: Frequent relapse, IFR: Infrequent relapser, SD: Standard deviation
Table 2: Correlation of FR with age and sex (n=160)
Factors n (%) p value
IFR FR
Age group (years)
≤1 2 (66.67) 1 (33.33) 0.4059
1-8 81 (57.45) 60 (42.55)
>8 9 (56.25) 7 (43.75)
Mean±SD 4.24±2.24 4.5±2.4
Sex
Male 62 (63.9) 35 (36.1) 0.0609
Female 30 (47.6) 33 (52.4)
Total 92 (100) 68 (100)
FR: Frequent relapse, IFR: Infrequent relapser, SD: Standard deviation
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Although shown in the previous studies [5,6,10,15-16], we 
did not find any correlation between age at presentation and 
future relapses. As in our study, several studies also reported 
that there is no significant correlation between sex and 
FR [5,6,10,1617].
Ali et al. [10] and Noer et al. [18] found hematuria as a 
significant risk factor for the FR. This finding was not supported 
by Cho et al. [19]; although the presence or absence of hematuria 
was not determined in our study. In our study, there was no 
relationship between relapse and serum albumin levels which 
is supported by the findings of a study by Anderson et al. [15]. 
However, Sarker et al. showed that the low serum albumin and 
low serum total protein were related with FR [16]. Azotemia was 
not significantly related to FR in our study, similar to the study 
by Ali et al. [10].
The mean time taken to achieve remission was significantly 
associated with FR in our study. This finding was supported by 
many other studies [9,10,19-21]. Hence, while we are treating 
NS children, time taken to achieve remission should be properly 
noted. Mean duration of interval between remission and first 
relapse was significantly associated with FR in our study which 
is also reported in other studies [6,18]. Relapses were triggered 
by urinary tract infections and respiratory tract infections 
significantly in our study as reported by Sarker et al. [16], Noer 
et al. [18], and Misra et al. [22]. Hypertension is another factor 
significantly associated with FR in our study as similar to the 
study by Prasun et al. [9].
For IFR, prednisolone (2 mg/kg/day) is given until urine 
dipstick shows nil or trace for three consecutive days and then 
prednisolone 1.5 mg/kg on alternate days for 4 weeks. In FR/
steroid dependent children, they were referred for evaluation 
for alternate day prednisolone to maintain remission and to 
assess steroid threshold. In FRNS and SDNS, the choices 
include extended low dose (0.5-0.75 mg/kg) alternate day 
steroids for 6-18 months. In the case of steroid toxicity and 
threshold >0.5 mg/kg on alternate days, alternate medications 
such as levamisole, cyclophosphamide, mycophenolate mofetil, 
tacrolimus, and cyclosporine may be considered. In steroid 
resistance patients, the child referred for renal biopsy as therapy 
was based on the renal biopsy findings.
Anderson et al. [15] found a significant relationship between 
prolonged steroid therapy (>12 weeks) and reduction in relapse 
frequency in their study. For the treatment of an initial episode 
of NS, alternate day steroid therapy to be given from 8 weeks 
to 5 months with tapering of the dose [2]. When planning the 
duration of steroid therapy, the side effects of prolonged corticoid 
steroid administration must be kept in mind. In future, stopping 
steroid therapy as a factor affecting relapse should be studied 
whether abrupt stopping of steroids after 6 weeks or prolonged 
duration of steroids with tapering of the dose is helpful to 
decrease the relapse. If we give importance to factors which 
are associated with FR in NS, it would be helpful for follow-up 
and long-term management of the children with NS. It will be 
helpful to counsel the parents of children with NS, for better drug 
compliance and for starting alternative drugs, to develop better 
treatment protocols in future.
CONCLUSION
Our study suggests that IFRs were more than the FRs with 
male predominance in children with NS. More than 14 days to 
achieve remission during the first episode, relapse within first 
6 months, associated infections and hypertension were the factors 
significantly associated with FRs in childhood SSNS. These 
factors should be kept in mind and should be well documented 
at the time of initial presentation of NS for the long-term 
management.
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